In:
The Journal of Immunology, The American Association of Immunologists, Vol. 204, No. 1_Supplement ( 2020-05-01), p. 86.55-86.55
Abstract:
One risk of allogeneic blood transfusion is the development of alloantibodies against red blood cell (RBC) antigens not found on the recipient’s RBC. The monocyte monolayer assay (MMA) is an in vitro model which has been used to determine the clinical significance of alloantibodies and predict post-transfusion RBC survival. We aimed to develop a semi-automated procedure to reduce assay time and facilitate improved patient management. METHODS PBMCs isolated using Sepmate tubes (STEMCELL Technologies) were added to Lab-Tek 8-well chamber slides (37°C, 1 hr, CO2). Antigen matched RBC were sensitised with plasma with known anti-RBC antibodies (anti-D n=3, anti-Yta n=4) (37°C, 1 hr, CO2). A modified Wright-Giemsa staining protocol was performed (Aerospray Hematology Pro 2 stainer, ELITechGroup) and the proportion of bound and/or phagocytosed RBC was determined via microscopy ( & gt;5% considered clinically significant). RESULTS The introduction of PBMC isolation using sepmate tubes and automated cell staining reduced technical requirements, improved assay reproducibility and reduced assay time by & gt;2 hours. For the alloantibodies tested, 67% of the anti-D and none of the anti-Yta were clinically significant. CONCLUSIONS We developed a MMA with improved reproducibility and reduced turnaround time. This assay will improve blood transfusion safety and facilitate better patient management by reducing the risk of incompatible blood transfusion.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.204.Supp.86.55
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2020
detail.hit.zdb_id:
1475085-5
Permalink